ALNY
Price
$397.55
Change
-$15.08 (-3.65%)
Updated
Dec 12 closing price
Capitalization
52.52B
60 days until earnings call
Intraday BUY SELL Signals
XCUR
Price
$6.35
Change
+$0.28 (+4.61%)
Updated
Dec 12 closing price
Capitalization
40.47M
Intraday BUY SELL Signals
Interact to see
Advertisement

ALNY vs XCUR

Header iconALNY vs XCUR Comparison
Open Charts ALNY vs XCURBanner chart's image
Alnylam Pharmaceuticals
Price$397.55
Change-$15.08 (-3.65%)
Volume$1.66M
Capitalization52.52B
Exicure
Price$6.35
Change+$0.28 (+4.61%)
Volume$224.24K
Capitalization40.47M
ALNY vs XCUR Comparison Chart in %
View a ticker or compare two or three
VS
ALNY vs. XCUR commentary
Dec 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and XCUR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 14, 2025
Stock price -- (ALNY: $412.63 vs. XCUR: $6.07)
Brand notoriety: ALNY and XCUR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 116% vs. XCUR: 66%
Market capitalization -- ALNY: $52.52B vs. XCUR: $40.47M
ALNY [@Biotechnology] is valued at $52.52B. XCUR’s [@Biotechnology] market capitalization is $40.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileXCUR’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • XCUR’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than XCUR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 4 TA indicator(s) are bullish while XCUR’s TA Score has 5 bullish TA indicator(s).

  • ALNY’s TA Score: 4 bullish, 4 bearish.
  • XCUR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ALNY and XCUR are a good buy in the short-term.

Price Growth

ALNY (@Biotechnology) experienced а -11.33% price change this week, while XCUR (@Biotechnology) price change was -9.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

ALNY is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($52.5B) has a higher market cap than XCUR($40.5M). ALNY has higher P/E ratio than XCUR: ALNY (1325.17) vs XCUR (0.19). ALNY YTD gains are higher at: 75.356 vs. XCUR (-55.596). ALNY has higher annual earnings (EBITDA): 187M vs. XCUR (-8.71M). ALNY has more cash in the bank: 2.73B vs. XCUR (4.44M). XCUR has less debt than ALNY: XCUR (366K) vs ALNY (1.31B). ALNY has higher revenues than XCUR: ALNY (3.21B) vs XCUR (0).
ALNYXCURALNY / XCUR
Capitalization52.5B40.5M129,630%
EBITDA187M-8.71M-2,146%
Gain YTD75.356-55.596-136%
P/E Ratio1325.170.19709,252%
Revenue3.21B0-
Total Cash2.73B4.44M61,402%
Total Debt1.31B366K357,377%
FUNDAMENTALS RATINGS
ALNY vs XCUR: Fundamental Ratings
ALNY
XCUR
OUTLOOK RATING
1..100
6239
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
39
Fair valued
PROFIT vs RISK RATING
1..100
12100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
5044
P/E GROWTH RATING
1..100
56100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XCUR's Valuation (39) in the null industry is somewhat better than the same rating for ALNY (100) in the Biotechnology industry. This means that XCUR’s stock grew somewhat faster than ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for XCUR (100) in the null industry. This means that ALNY’s stock grew significantly faster than XCUR’s over the last 12 months.

XCUR's SMR Rating (99) in the null industry is in the same range as ALNY (100) in the Biotechnology industry. This means that XCUR’s stock grew similarly to ALNY’s over the last 12 months.

XCUR's Price Growth Rating (44) in the null industry is in the same range as ALNY (50) in the Biotechnology industry. This means that XCUR’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for XCUR (100) in the null industry. This means that ALNY’s stock grew somewhat faster than XCUR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYXCUR
RSI
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
65%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
69%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
63%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
67%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
64%
Bearish Trend 20 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signal:
Gain/Loss:
XCUR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VCR398.331.66
+0.42%
Vanguard Consumer Discretionary ETF
ACVF49.820.14
+0.28%
American Conservative Values ETF
TIME25.200.03
+0.12%
Clockwise Core Equity & Innovation ETF
BSJX25.64-0.01
-0.04%
Invesco BulletShares 2033 Hi YldCrpBdETF
QJUN31.76-0.04
-0.14%
FT Vest Nasdaq-100 Buffer ETF - Jun

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with ARGX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
+2.02%
ARGX - ALNY
52%
Loosely correlated
-0.07%
IONS - ALNY
42%
Loosely correlated
+0.65%
SGMO - ALNY
42%
Loosely correlated
-4.87%
INSM - ALNY
37%
Loosely correlated
+2.84%
ALLO - ALNY
37%
Loosely correlated
+4.73%
More

XCUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XCUR has been loosely correlated with XFOR. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XCUR jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XCUR
1D Price
Change %
XCUR100%
+14.10%
XFOR - XCUR
34%
Loosely correlated
-0.26%
CYCN - XCUR
27%
Poorly correlated
-2.33%
ALNY - XCUR
26%
Poorly correlated
+2.02%
NNVC - XCUR
25%
Poorly correlated
-1.52%
HRTX - XCUR
25%
Poorly correlated
N/A
More